Navigation Links
AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
Date:2/25/2010

he company's own AFFITOME(R) technology. However, for the first time it is now being used against a human hormone. The reason for this announcement is the gratifying approval of significant development funds by the Austrian Research Promotion Agency, FFG.

Today, Viennese biotech company AFFiRiS AG announced the start of a new program to develop a vaccine against hypertension. This means that there are now four of the company's current seven development projects in the public domain. The specific reason for the "outing" of project no. 4 was the approval of public research promotion funds by the FFG. The vaccine is targeting angiotensin II, a peptide hormone that can cause narrowing of the blood vessels and thereby hypertension.

Dr. Walter Schmidt, CEO of AFFiRiS AG comments on the company's development pipeline: "With projects in seven different indications at the moment, AFFiRiS AG has achieved a broad diversification of potential development risks. While building up this pipeline we were consequently guided by our strategic focus, which is targeting disease areas with very large numbers of patients and lack of optimal therapies. We believe that systematic risk distribution, together with a focus on indications with a high market potential is the key for substantial success of a biotechnology company. The early VC investment by MIG Fonds AG, Munich, was of substancial importance for the establishment of our strong development pipeline. Our first licensing agreement on our Alzhe
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. Persistent Vaccination Effect of GRAZAX(R) After Completion of Treatment
7. New study indicates smallpox vaccination effective for decades
8. New study indicates smallpox vaccination effective for decades
9. Insect cells provide the key to alternative swine flu vaccination
10. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets  has ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... (either DNA or RNA) into cells. This technology helps ... cells and protein metabolism by affecting the nuclear genes. ...
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Corporation is,pleased to announce it has obtained US FDA ... C-QUR Edge(TM) V-Patch and C-QUR Lite(TM),V-Patch., These new ... and,reinforcement of soft tissue, including hernia repair -- a ... each year. This novel,technology combines Atrium,s ProLite Ultra(TM) polypropylene ...
... ENMD-2076, ROCKVILLE, Md., May 8 ... developing therapeutics for,the treatment of cancer and ... has joined the University of Colorado Cancer,Center ... ENMD-2076 in advanced cancer,patients. Dr. Geoffrey Shapiro, ...
... May 7, 2008 / b3c newswire / – ... entered into a joint agreement to supply customers ... complex structures. , Under the agreement, CRELUX and ... crystal-grade protein kinase portfolio, optimized and quality-controlled for ...
Cached Biology Technology:Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 3CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 2CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform 3
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
(Date:7/11/2014)... study the proteins that let nerve cells send out ... upon a biological tactic that may offer a new ... safe and environmentally responsible way. , Their findingthat ... species and harmless for a closely related onesuggests that ... harming beneficial species like bees. A summary of the ...
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... Everyone wants to live in the nicest possible house, ... at Tufts University,s School of Arts and Sciences and ... locate new and improved housing using previously unknown social ... experiments and computer models to uncover some surprising new ...
... Here,s another reason to kick the soda habit. New ... ( http://www.fasebj.org ) shows that high levels of phosphates ... than once thought. That,s because researchers found that the ... phosphate levels may also increase the prevalence and severity ...
... 23, 2010) Moffitt Cancer Center announces steadily growing ... for selecting chemotherapy for Non Small Lung Cancer patients. ... with lung cancer. The ERCC1 Analysis measures ERCC1 ... The correlation between ERCC1 levels and therapy ...
Cached Biology News:Social networking helps hermit crabs find homes 2Social networking helps hermit crabs find homes 3Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists 2Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer 2
... are complete ready-to-use reagents for the isolation ... specifically formulated for the isolation of genomic ... specifically formulated for the isolation of genomic ... DNAzol Reagents can be used for restriction ...
Apoptosis Detection Systems and Reagents...
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: